INT-220

N/A

Report date: 2025/01/26 19:09:46

Base Information

Drug NameINT-220
Drug Alias Namenanobody-Fc fusion protein (Intract Pharma)INT-220
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntract Pharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIntract Pharma Ltd
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A